Recombinant multi-species IKZF5 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine IKZF5 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Members of the Ikaros (ZNFN1A1; MIM 603023) family of transcription factors, which includes Pegasus, are expressed in lymphocytes and are implicated in the control of lymphoid development.[supplied by OMIM, Jul 2002]
The Alternative Names of target: IKZF5,Zinc finger protein Pegasus,Ikaros family zinc finger protein 5,THC7,PEGASUS,ZNFN1A5
Go
to IKZF5 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP2548-Ab-1/ GM-Tg-hg-IP2548-Ab-2 | Human IKZF5 protein | Human |
GM-Tg-rg-IP2548-Ab-1/ GM-Tg-rg-IP2548-Ab-2 | Rat IKZF5 protein | Rat |
GM-Tg-mg-IP2548-Ab-1/ GM-Tg-mg-IP2548-Ab-2 | Mouse IKZF5 protein | Mouse |
GM-Tg-cynog-IP2548-Ab-1/ GM-Tg-cynog-IP2548-Ab-2 | Cynomolgus/Rhesus macaque IKZF5 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP2548-Ab-1/ GM-Tg-felg-IP2548-Ab-2 | Feline IKZF5 protein | Feline |
GM-Tg-cang-IP2548-Ab-1/ GM-Tg-cang-IP2548-Ab-2 | Canine IKZF5 protein | Canine |
GM-Tg-bovg-IP2548-Ab-1/ GM-Tg-bovg-IP2548-Ab-2 | Bovine IKZF5 protein | Bovine |
GM-Tg-equg-IP2548-Ab-1/ GM-Tg-equg-IP2548-Ab-2 | Equine IKZF5 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. |
GM-Tg-hg-IP2548-Ab-1/ GM-Tg-hg-IP2548-Ab-2;
GM-Tg-rg-IP2548-Ab-1/ GM-Tg-rg-IP2548-Ab-2;
GM-Tg-mg-IP2548-Ab-1/ GM-Tg-mg-IP2548-Ab-2; GM-Tg-cynog-IP2548-Ab-1/ GM-Tg-cynog-IP2548-Ab-2; GM-Tg-felg-IP2548-Ab-1/ GM-Tg-felg-IP2548-Ab-2; GM-Tg-cang-IP2548-Ab-1/ GM-Tg-cang-IP2548-Ab-2; GM-Tg-bovg-IP2548-Ab-1/ GM-Tg-bovg-IP2548-Ab-2; GM-Tg-equg-IP2548-Ab-1/ GM-Tg-equg-IP2548-Ab-2 |
Products Name | IKZF5 protein |
Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
Target Name | IKZF5 |
Protein Sub-location | Introcelluar Protein |
Isotypes | Recombinant protein |
Expression platform | Mammalian cell |
Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
Tag | His |
Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine IKZF5 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab
GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.